i
Risk-Benefit Analysis of RSV Vaccination in Older Adults
-
June 26, 2024
Details:
-
Personal Author:
-
Corporate Authors:
-
Conference Authors:
-
Description:09-RSV-Adult-Hutton-508.pdf
-
Subjects:
-
Series:
-
Document Type:
-
Name as Subject:
-
Genre:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:urn:sha256:7aa550cb944c4294a3ac16f5b3d76b0c61528f902a4002a8869dfaf31a6fc81b
-
Download URL:
-
File Type:
Related Documents
-
- Personal Author:Bergren, NicholasJune 26, 2024 | ACIP meeting Respiratory Syncytial Virus Vaccines – AdultDescription:Dengue Tetravalent Vaccine (Live, Attenuated) [Dengvaxia®] is being discontinued due to low demand.This decision is not due to any concerns regarding...Personal Author:Ortega-Sanchez, Ismael R.June 26, 2024 | ACIP meeting Respiratory Syncytial Virus Vaccines – AdultDescription:Evidence to Recommendations Framework (EtR) : RSV Vaccination in Adults Aged 50–59 years, 60–74 years, and 75 years and older